drugset / Trial / NCT00141193

Prevention of Colorectal Sporadic Adenomatous Polyps (PRESAP)

NCT00141193

Phase 3 Completed 1561 enrolled Pfizer
RandomizedParallel-groupDouble-blindTreatment

Summary

This study is a prospective, randomized, double-blind, placebo-controlled, multi-center trial to compare the efficacy and safety of celecoxib 400mg QD versus placebo in reducing the occurrence of new colorectal adenomas post-polypectomy at Month 13 (Year 1) and Month 37 (Year 3) of study drug administration.

Timeline

Start
2001-02
Primary completion
2007-05
Completion
2007-05

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Celecoxib Other / unclassified 400 mg Oral

Indications